Related Experiment Video

Updated: Jul 18, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Rheumatology in 2006: crossroads or crisis?

David S Pisetsky1

  • 1Departmentof Medicine, Division of Rheumatology and Immunology, Duke UniversityMedical Center, Durham, NC, USA.

Bulletin of the NYU Hospital for Joint Diseases
|November 24, 2006
PubMed

Insights

Rheumatology has seen significant treatment advances due to new drugs. However, future progress faces challenges in research direction and data systems, despite opportunities in personalized medicine.

Area of Science:

  • Rheumatology
  • Biomedicine
  • Personalized Medicine

Background:

  • The past decade has seen remarkable advances in rheumatology patient treatment, driven by numerous new drug approvals and clinical trials.
  • Despite these advances, concerns exist regarding the sustainability of momentum in rheumatologic research and treatment.

Purpose of the Study:

  • To highlight recent advancements in rheumatology treatments.
  • To identify challenges and opportunities for the future of rheumatology research and patient care.

Main Methods:

  • Review of recent drug approvals and ongoing clinical trials in rheumatology.
  • Analysis of current research agendas for major rheumatologic diseases.
  • Assessment of informatics systems for treatment risk/benefit evaluation.
  • Examination of clinical trial designs for rheumatoid arthritis (RA).

Main Results:

  • Significant progress in drug development for various rheumatologic conditions.
  • Identified uncertainties in research priorities for osteoarthritis and fibromyalgia.
  • Lack of robust informatics systems hinders accurate risk-benefit assessment.
  • Limited clinical trials in rheumatoid arthritis focus on sustained remission or cure.

Conclusions:

  • Future opportunities in rheumatology are bright, supported by advances in biomedicine and outcomes assessment.
  • Development of personalized medicine approaches offers potential for individualized treatment strategies.
  • Addressing research agenda uncertainties and improving data systems are crucial for sustained progress.

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...